| 000 | 01894 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250515073347.0 | ||
| 264 | 0 | _c20071031 | |
| 008 | 200710s 0 0 eng d | ||
| 022 | _a0007-1188 | ||
| 024 | 7 |
_a10.1038/sj.bjp.0707285 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWang, Y | |
| 245 | 0 | 0 |
_aPost-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. _h[electronic resource] |
| 260 |
_bBritish journal of pharmacology _cAug 2007 |
||
| 300 |
_a1377-84 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 | _aBlood-Brain Barrier |
| 650 | 0 | 4 |
_aBrain Ischemia _xdrug therapy |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
| 650 | 0 | 4 | _aEpoetin Alfa |
| 650 | 0 | 4 |
_aErythropoietin _xadministration & dosage |
| 650 | 0 | 4 |
_aHematinics _xadministration & dosage |
| 650 | 0 | 4 | _aHematocrit |
| 650 | 0 | 4 |
_aInfarction, Middle Cerebral Artery _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMicroglia _xdrug effects |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xadministration & dosage |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Wistar |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 |
_aStroke _xdrug therapy |
| 700 | 1 | _aZhang, Z G | |
| 700 | 1 | _aRhodes, K | |
| 700 | 1 | _aRenzi, M | |
| 700 | 1 | _aZhang, R L | |
| 700 | 1 | _aKapke, A | |
| 700 | 1 | _aLu, M | |
| 700 | 1 | _aPool, C | |
| 700 | 1 | _aHeavner, G | |
| 700 | 1 | _aChopp, M | |
| 773 | 0 |
_tBritish journal of pharmacology _gvol. 151 _gno. 8 _gp. 1377-84 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.bjp.0707285 _zAvailable from publisher's website |
| 999 |
_c17139920 _d17139920 |
||